Strategic Focus Nextech Invest is a cancer therapeutics focused venture capital firm headquartered in Zurich, with a global portfolio across the US and Europe, presenting opportunities to align portfolio companies with potential co-investors, strategic exits, or founder-friendly capital solutions in oncology.

Active Funding Recent investments and high-profile rounds (Stipple Bio Series A, Delphia Therapeutics Series A, FogPharma Series E, Boundless Bio Series B) indicate ongoing capital deployment and appetite for leading oncology platforms, signaling open doors for co-lead investments, syndication, or strategic financing partnerships.

Portfolio Synergies Nextech consistently backs multi-medicine oncology platforms and ECBS/precision oncology players, suggesting opportunities to propose collaboration, licensing, or M&A advisory services with synergy potential across portfolio companies and adjacent therapeutic modalities.

Growth Mobility With a revenue range of 10-25 million and a relatively compact team, Nextech may value scalable technology, data-driven diligence, and cost-efficient collaboration models that accelerate due diligence, portfolio value creation, and time-to-close for co-investments.

Global Access Having a global reach and notable European and US activity, Nextech is well-positioned for cross-border co-investment structures, regional market entry support, and introductions to strategic partners and researchers across continents.